Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1445358
This article is part of the Research Topic Community Series in Reducing Adverse Effects of Cancer Immunotherapy: Volume II View all 13 articles

Case Report: Fatal hemoptysis after effective treatment with Tislelizumab and Anlotinib in Pulmonary sarcomatoid carcinoma-a case report

Provisionally accepted
Chen-Wei Pu Chen-Wei Pu *Zhen-Zhen Wang Zhen-Zhen Wang *Yong-Fen Ma Yong-Fen Ma *
  • Zibo Central Hospital, Shandong, China

The final, formatted version of the article will be published soon.

    Pulmonary sarcomatoid carcinoma (PSC), a rare non-small cell lung cancer (NSCLC) subtype, poses diagnostic and treatment difficulties. Current research explores targeted therapies and immunotherapy to improve patient outcomes. This case report details a male patient diagnosed with PSC via pathology. Tests revealed high levels of PD-L1, a marker suggesting potential benefit from immune checkpoint inhibitors. However, despite bronchoscopic intervention, his advanced stage IIIB cancer (cT3N2bM0) progressed quickly, with progression-free survival (PFS) under 3 months. Following progression, the patient received tislelizumab (anti-PD-1 antibody) and anlotinib (an anti-angiogenic drug) as second-line therapy. This combination showed promise, achieving near-partial remission after the first cycle. Subsequent scans documented continued tumor shrinkage until the patient experienced fatal hemoptysis. This case highlights the potential benefits of combining tislelizumab with anlotinib for PSC. However, it also represents the first reported case of fatal hemoptysis with this specific treatment regimen. This finding emphasizes the need for increased awareness of this potential complication, especially in patients with centrally located PSC treated with anti-angiogenic agents like anlotinib.

    Keywords: tislelizumab, Anlotinib, Pulmonary sarcomatoid carcinoma, Hemoptysis, adverse effects

    Received: 05 Jul 2024; Accepted: 09 Sep 2024.

    Copyright: © 2024 Pu, Wang and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Chen-Wei Pu, Zibo Central Hospital, Shandong, 255000, China
    Zhen-Zhen Wang, Zibo Central Hospital, Shandong, 255000, China
    Yong-Fen Ma, Zibo Central Hospital, Shandong, 255000, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.